* Pacific Biosciences of California Inc PACB.OQ
PACB.O is
expected to show a fall in quarterly revenue when it reports
results on February 16.
* The Menlo Park California-based company is expected to
report
a 27.2% decrease in revenue to $26.237 million from $36.02
million a year ago, according to the mean estimate from 7
analysts, based on Refinitiv data. The company's guidance on
January 9 2023, for the period ended December 31, was for
revenue of $27.300 million.
* Refinitiv's mean analyst estimate for Pacific Biosciences
of
California Inc is for a loss of 36 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Pacific
Biosciences of California Inc is $12.5, above its last closing
price of $10.28.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 -0.33 -0.33 -0.34 Missed -2.5
Jun. 30 2022 -0.32 -0.32 -0.32 Met 1
Mar. 31 2022 -0.31 -0.31 -0.37 Missed -20
Dec. 31 2021 -0.28 -0.28 -0.31 Missed -9.4
Sep. -0.22 -0.22 -0.23 Missed -5.7
30 2021
Jun. 30 2021 -0.20 -0.21 -0.21 Met -1.9
Mar. 31 2021 -0.45 -0.46 -0.45 Beat 1.7
Dec. 31 2020 0.30 0.32 0.37 Beat 16.4
This summary was machine generated February 14 at 23:55 GMT.
All figures in US dollars unless otherwise stated